Atheroarteritis: A combined immunological and lipid imbalance

International Journal of Cardiology

Volumn 54, Issue SUPPL., 1996, Pages

  Wissler, Robert W ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Arterial inflammation; Atheroarteritis; Immunological and lipid imbalance; Pathogenetic hypotheses

Indexed keywords

OXIDIZED LOW DENSITY LIPOPROTEIN;

ARTERITIS; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNITY; CLINICAL RESEARCH; CONFERENCE PAPER; ENDOTHELIUM INJURY; ETIOLOGY; GLYCOSYLATION; HUMAN; IMMUNOPATHOGENESIS; LIPID OXIDATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0029790901     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/0167-5273(95)02634-7     Document Type: Conference Paper

References (126)

1. Hudson RE. Other arterial diseases. In: Hudson RE, ed. Cardiovascular pathology. Baltimore: The Williams & Wilkins Co., 1965;531-537.
2. Edwards JE. Acquired diseases of the thoracic aorta. Med Clin North Am 1958;42:1011-1021.
3. Edwards JE. Branches of aortic arch. In: Edwards JE, ed. An atlas of acquired diseases of the heart and great vessels. Philadelphia: W.B. Saunders & Co., 1961;678-679,1237-1239.
4. Heggtveit HA. Nonatherosclerotic diseases of the aorta. In: Silver MD, ed. Cardiovascular pathology. New York: Churchill Livingston, 1983;715-717.
5. Rose AG. Diseases of medium-sized arteries, including hypertension. In: Silver MD, ed. Cardiovascular pathology. New York: Churchill Livingston, 1983;774.
6. Datta BN. Cardiovascular disease in the tropics. In: Silver MD, ed. Cardiovascular pathology. New York: Churchill Livingston, 1983;1138-1139.
7. Longcope WT, Rackemann FM. The relation of circulating antibodies to serum disease. J Exp Med 1918;27:341-358.
8. MacKenzie GM, Leake WH. Relation of antibody and antigen to serum disease susceptibility. J Exp Med 1921;33:601-620.
9. Rich AR. The role of hypersensitivity in periarteritis nodosa. Bull Johns Hopkins Hosp 1942;71:123-140.
10. Rich AR. Additional evidence of the role of hypersensitivity in the etiology of periarteritis nodosa: Another case associated with sulfonamide reaction. Bull Johns Hopkins Hosp 1942;71:375-379.
11. Rich AR, Gregory JE. The experimental demonstration that periarteritis nodosa is a manifestation of hypersensitivity. Bull Johns Hopkins Hosp 1943;72:65-88.
12. Hopps HC, Wissler RW. The experimental production of generalized arteritis and periarteritis (periarteritis nodosa). J Lab Clin Med 1946;31:939-957.
13. Rich AR, Gregory JE. Experimental anaphylactic lesions of coronary arteries of the 'sclerotic' type, commonly associated with Rheumatic Fever and Disseminated lupus erythematosus. Bull Johns Hopkins Hosp 1947;81:312-324.
14. Germuth FG Jr. A comparative histologic and immunologic study in rabbits of induced hypersensitivity of the serum sickness type. J Exp Med 1953;97:257.
15. Germuth FG Jr, Pace MG, Tippett JC. Comparative histologic and immunologic studies in rabbits of induced hypersensitivity of the serum sickness type: II. The effect of sensitization to homologous and cross-reactive antigens on the rate of antigen elimination and the development of allergic lesions. J Exp Med 1955;101:135.
16. Dixon FJ, Vazquez JJ, Weigle WO, Cochrane CG. Pathogenesis of serum sickness. Arch Pathol 1958;65:18-28.
17. Dixon FJ. The role of antigen-antibody complexes in disease. In: The Harvey lectures, Series 58. New York: Academic Press, 1963;21-52.
18. Beaumont JL. L'hyperlipidemie par auto-anticorps anti-β-lipoproteine. Une nouvelle entite pathologique. C.R. Acad Sci Paris, Serie D. 1965;261:4563-4566.
19. Beaumont JL, Beaumont V. Immunological factors of atherosclerosis. In: Schettler G, Weizel A, eds. Atherosclerosis III. Berlin: Springer Verlag, 1974;579-589.
20. Beaumont JL, Antonucci M, Berard M. Autoimmune hyperlipidemia in the nephrotic syndrome. In: Manning GW, Haust MD, eds. Atherosclerosis: metabolic, morphologic, and clinical aspects. New York: Plenum Press, 1977;152-154.
21. 1A globulin in the human atherosclerotic plaque. Circulation 1970;42:16.
22. Hollander W, Kramsch DM. Identification of collagen-bound immunoglobulin G (IgG) in the human atherosclerotic plaque. Circulation 1972;45:259.
23. Hollander W, Colombo MA, Kramsch DM, Kirkpatrick B. Immunological aspects of atherosclerosis. Comp Pathol Heart Adv Cardiol 1974;13:192-207.
24. Minick CR, Murphy GE, Campbell GC. Experimental induction of athero-arteriosclerosis by the synergy of allergic injury to arteries and lipid-rich diet. I. Effect of repeated injections of horse serum in rabbits fed a dietary cholesterol supplement. J Exp Med 1966;124:635-651.
25. Minick CR, Murphy GE. Experimental induction of atheroarteriosclerosis by the synergy of allergic injury to arteries and lipid-rich diet. II. Effect of repeatedly injected foreign protein in rabbits fed a lipid-rich, cholesterol-poor diet. Am J Pathol 1973;73:265-292.
26. Minick CR. Immunologic arterial injury in atherogenesis. Ann NY Acad Sci 1976;275:210-227.
27. Fabricant CG. Herpesvirus induced cholesterol - an added dimension in the pathogenesis, prophylaxis, or therapy of atherosclerosis. Artery I 1975;361.
28. Fabricant CG, Fabricant J, Litrenta MM, Minick CR. Virus-induced atherosclerosis. J Exp Med 1978;148:335-340.
29. Fabricant CG, Fabricant J, Minick CR, Litrenta MM. Herpesvirus-induced atherosclerosis. Cold Spring Harbor Conf Cell Prolif 1980;7:1251-1258.
30. Fabricant CG, Hajjar DJ, Minick CR, Fabricant J. Herpesvirus infection enhances cholesterol and cholesteryl ester accumulation in cultured arterial smooth muscle cells. Am. J Pathol 1981;105:176-184.
31. Fabricant J, Fabricant CG, Litrenta MM, Minick CR. Vaccination prevents atherosclerosis induced by Marek's disease herpesvirus. Fed Proc 1981;40:335.
32. Minick CR, Fabricant CG, Fabricant J, Litrenta MM. Atheroarteriosclerosis induced by infection with a herpesvirus. Am J Pathol 1979;6:673-706.
33. Minick CR, Fabricant J, Fabricant CG, Litrenta MM. Pathogenesis of herpesvirus-induced atherosclerosis. Circulation 1979;59 and 60(suppl. II):168.
34. Fabricant CG, Fabricant J, Minick CR, Litrenta MM. Herpesvirus-induced atherosclerosis in chickens. Fed Proc 1983;42:2476-2479.
35. Dixon F, Croker B, Del Villano B, Jensen F, Lerner R. Oncornavirus infection and 'auto' immune complex disease of mice. In: Brent L, Holborow J, eds. Progress in immunology II, Vol. 5. Amsterdam: North-Holland Publishing Co., 1974;49-55.
36. Benditt EP, Barrett T, McDougall JK. Viruses in the etiology of atherosclerosis. Proc Natl Acad Sci 1983;80: 6386-6389.
37. Yamashiroya HM, Ghosh L, Yang R, Robertson AL. Herpes viridae in the coronary arteries and aorta of young trauma victims. Am J Pathol 1988;130:71-79.
38. Bulkley BH, Roberts WC. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. Am J Med 1975;58:243-264.
39. Virchow R. Virchow and the cellular pathology. In: Long ER ed. A History of Pathology. New York: Dover Publications, Inc., 1928;114-126.
40. Rose GA, Spencer H. Polyarteritis nodosa. Q J Med 1957;26:43.
41. Cochrane CG. Immune complex-mediated tissue injury. In: Cohen S, Ward PA, McCluskey RT, eds. Mechanisms of immunopathology. New York: Wiley, Inc., 1979;29-48.
42. Abbas AK, Lichtman AH, Pober JS. Diseases caused by humoral and cell-mediated immune reactions. In: Abbas AK, Lichtman AH, Pober JS, eds. Cellular and molecular iogy. Philadelphia: W.B. Saunders Co., 1991; 358-360.
43. Wissler RW, Vesselinovitch D, Davis HR, Lambert PH, Bekermeier M. A new way to look at atherosclerotic involvement of the artery wall and the functional effects. Part II. Pathogenesis of human and experimental atherosclerosis. Ann NY Acad Sci 1985;454:9-22.
44. Wissler RW, Vesselinovitch D, Davis HR, Yamada T. The composition of the evolving atherosclerotic plaque. In: Strandess D, Didisheim P, Clowes A, Watson J, editors. Vascular diseases: current research and clinical applications. Orlando: Grune and Stratton, 1987;241-256.
45. Wissler RW, Vesselinovitch D, Davis HR. Cellular components of the progressive atherosclerotic process. In: Olsson AG, ed. Atherosclerosis: biology and clinical science. Edinburgh: Churchill Livingstone, 1987;57-73.
46. Wissler RW, Vesselinovitch D. The development and use of animal models in atherosclerosis research. In: Gallo LL, ed. Cardiovascular disease. New York: Plenum Press, 1987;337-357.
47. Yamada T, Press M, Vesselinovitch D, Wissier RW. Quantitative ultrastructural analysis of coronary atheroscleoritc involvement in two macaque species. Exp Mol Pathol 1988;48:1-23.
48. Wissler RW, Vesselinovitch D. Animal models for hyperlipidemia-induced atherosclerosis. In: Paoletti R, Kritchevsky D, Holmes WL, eds. Drugs affecting lipid metabolism. Berlin: Springer-Verlag, 1987;111-116.
49. Wissler RW, Vesselinovitch D. Can atherosclerotic plaques regress? Anatomic and biochemical evidence from non-human animal models. Am J Cardiol 1990;65: 33F-40F.
50. Wissler RW, Vesselinovitch D. The time course of atherosclerotic lesion regression in macaque monkeys. In: Descovitch GC, Gaddi A, Magri GL, Lenzi S, eds. Atherosclerosis and cardiovascular disease: 7th International Meeting. Dordrecht: Kluwer Academic Publishers, 1990;391-400.
51. Poskitt TR, Fortwengler HP Jr, Bobrow JC, Roth GJ. Naturally occurring immune-complex glomerulonephritis in monkeys (Macaca irus). I. Light, immunoflourescence, and electron microscopic studies. Am J Pathol 1974;76:145-164.
52. Giddens WE Jr, Boyce JT, Blakley GA, Morton WR. Renal disease in the pigtailed macaque macaque (Macaca nemestrina). Vet Pathol 1981;18[Suppl. 6]:70-81.
53. Boyce JT, Giddens WE Jr, Seifert R. Spontaneous mesangioproliferative glomerulonephritis in pigtailed macaques (Macaca nemestrina). Vet Pathol 1981;18[Suppl. 6]: 82-88.
54. Wissler RW. Human transplant atheroarteritis and its relationship to other forms of risk factor engendered injury of the artery wall: summarizing presentation. In: Hauss WH, Wissler RW, Bauch HJ, eds. New pathogenic aspects of arteriosclerosis emphasizing transplantation atheroarteritis. Opladen: Westdeutscher Verlag, 1994; 137-145.
55. Thomson JG. Production of severe atheroma in a transplanted human heart. Lancet 1969;2:1088-1092.
56. Alonso DR, Starek PK, Minick CR. Studies on the pathogenesis of atheroarteriosclerosis induced in rabbit cardiac allografts by the synergy of graft rejection and hypercholesterolemia. Am J Pathol 1977;87:415-442.
57. Bulkely BH, Hutchins GM. Accelerated atherosclerosis: a morphologic study of 97 saphenous vein coronary artery bypass grafts. Circulation 1977;55:163-169.
58. Uys CJ, Rose AG, Barnard CN. The pathology of human cardiac transplantation. An assessment after 11 years' experience at Groote Schuur Hospital. S Afr Med J 1979;56:887-896.
59. Fitzmaurice M, Ratliff NB. Immunoglobulin deposition in atherosclerotic aortocoronary saphenous vein grafts. Arch Pathol Lab Med 1990;114:388-393.
60. Hansson GK, Geng YJ, Holm J, Stemme S. Lymphocyte adhesion and cellular immune reactions in chronic rejection and graft arteriosclerosis. Transpl Proc 1993;25:2050-2051.
61. Hansson GK, Jonasson L, Holm J, Bondjers G. Cellular composition of the human atherosclerotic plaque. Fed Proc 1984; 43:786.
62. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 1986;6:131-138.
63. Hansson GK, Lagerstedt E, Bengtsson A, Heideman M. IgG binding to cytoskeletal intermediate filaments activates the complement cascade. Exp Cell Res 1987;170:338-350.
64. Seifert PS, Hugo F, Hansson GK, Sucharit B. Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits. Lab Invest 1989;60:747-754.
65. Hansson GK, Jonasson L, Seifert PS, Stemme S. Immune mechanisms in atherosclerosis. Atherosclerosis 1989;9:567-578.
66. Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 1989;135:169-175.
67. Seifert PS, Hansson GK. Complement receptors and regulatory proteins in human atherosclerotic lesions. Arteriosclerosis 1989;9:802-811.
68. Hansson GK, Holm J. Interferon-gamma arterial stenosis after injury. Circulation 1991;84:1266-1272.
69. Stemme S, Fager G, Hansson GK. MHC class II antigen expression in human vascular smooth muscle cells is induced by interferon-gamma and modulated by tumour necrosis factor and lymphotoxin. Immunology 1990;69:243-249.
70. Libby P, Hansson GK. Biology of Disease. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest 1991;64:5-15.
71. Stemme S, Rymo L, Hansson GK. Polyclonal origin of T-lymphocytes in human atherosclerotic plaques. Lab Invest 1991;65:654-660.
72. Hansson GK, Seifert PS, Olsson G, Bondjers G. Immunohistochemical detection of macrophages and T-lymphocytes in atherosclerotic lesions of cholesterol-fed rabbits. Arterioscler Thromb 1991;11:745-750.
73. Hansson GK, Holm J, Holm S, Fotev Z, Hedrich HJ, Fingerle J. T lymphocytes inhibit the vascular response to injury. Proc Natl Acad Sci 1991;88:10530-10534.
74. 2-integrins. Scand J Immunol 1992;36:233-242.
75. Stemme S, Holm J, Hansson GK. T lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and the integrin VLA-1. Arterioscler Thromb 1992;12:206-211.
76. Geng YJ, Hansson GK, Holme E. Interferon-gamma and tumor necrosis factor synergize to induce nitric oxide production and inhibit mitochondrial respiration in vascular smooth muscle cells. Circ Res 1992;71: 1268-1276.
77. Hansson GK, Geng YJ, Holm J, Hardhammar P, Wennmalm A, Jennische E. Arterial smooth muscle cells express nitric oxide synthase in response to endothelial injury. J Exp Med 1994;180:733-738.
78. Geng YJ, Wu Q, Hansson GK. Protein kinase C activation inhibits cytokine-induced nitric oxide synthesis in vascular smooth muscle cells. Biochim Biophys Acta 1994;1223:125-132.
79. Hansson GK, Stemme S, Geng YJ, Holm J. Can immunocompetent cells and their cytokines play a role in atherogenesis? Nouv Rev Fr Hematol 1992;34[Suppl]: S43-S46.
80. Hansson GK. Immune and inflammatory mechanisms in the development of atherosclerosis. Br Heart J 1993;69[Suppl]:S38-S41.
81. Hansson GK. Immunological control mechanisms in plaque formation. Basic Res Cardiol 1994;89[Suppl]: 41-46.
82. Hansson GK. Cytokines regulate proliferation and cytoskeletal organization of vascular smooth muscle cells. Pathol Res Pract 1994;190:891-894.
83. Stemme S, Hansson GK. Immune mechanisms in atherogenesis. Ann Med 1994;26:141-146.
84. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T-lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci 1995;92:3893-3897.
85. Chisolm GM, Ma G, Irwin KC, et al. Seven β-hydroperoxycholest-5-en-3 β-o1, a component of human atherosclerotic lesions, is the primary cytotoxin of oxidized human low density lipoprotein. Proc Natl Acad Sci 1994;91:11452-11456.
86. Penn MS, Chisolm GM. Oxidized lipoproteins, altered cell function and atherosclerosis. Atherosclerosis 1994;108[Suppl]:S21-S29.
87. Witztum JL, Steinbrecher UP, Fisher M, Kesaniemi YA. Nonenzymatic glucosylation of homologous low density lipoprotein and albumin renders them immunogenic in the guinea pig. Proc Natl Acad Sci 1983;80:2757-2761.
88. Witztum JL, Steinbrecher UP, Kesaniemi YA, Fisher M. Autoantibodies to glucosylated proteins in the plasma of patients with diabetes mellitus. Proc Natl Acad Sci 1984;81:3204-3208.
89. Steinbrecher UP, Witztum JL. Glucosylation of low density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes 1984;33:130-134.
90. Witztum JL, Koschinsky T. Metabolic and immunological consequences of glycation of low density lipoproteins. In: Baynes JW, Monnier VM, eds. The Maillard reaction in aging, diabetes and nutrition. New York: Alan R. Liss Inc., 1989;219-234.
91. Nakamura Y, Horii Y, Nishino T, et al. Immunocytochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993;143:1649-1656.
92. Palinski W, Koschinsky T, Butler SW, et al. Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. Arterioscler Thromb Vasc Biol 1995;15:571-582.
93. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci 1984;81:3883-87.
94. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modification of low-density lipoprotein that increase its atherogenecity. N Engl J Med 1989;320:915.
95. Heinecke JW, Baker L, Rosen H, Chait A. Superoxide-mediated modification of low density lipoprotein by arterial smooth muscle cells. J Clin Invest 1986;77: 757-761.
96. Kita T, Nagano Y, Yokode M, et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal for familial hypercholesterolemia. Proc Natl Acad Sci 1987;84: 5928-5931.
97. Haberland ME, Fong D, Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science (Wash. DC) 1988;241:215-218.
98. Steinberg D. Metabolism of lipoproteins and their role in the pathogenesis of atherosclerosis. Atheroscler Rev 1988;18: 1-23.
99. Hessler JR, Robertson AL Jr, Chisolm GM. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 1979;32:213.
100. Henriksen T, Evensen SA, Carlander B. Injury to human endothelial cells in culture induced by low density lipoproteins. Scand J Clin Lab Invest 1979;39:361.
101. Hessler JR, Morel DW, Lewis LJ, Chisolm GM. Lipoprotein oxidation and lipoprotein-induced cytotoxicity. Arteriosclerosis 1983;3:215.
102. Chisolm GM. Antioxidants and atherosclerosis:a current assessment. Clin Cardiol 1991;14:125.
103. Murugesan G, Chisolm GM, Fox PL. Oxidized low density lipoprotein inhibits the migration of aortic endothelial cells in vitro. J Cell Biol 1993;120:1011.
104. Chisolm GM. Oxidized lipoproteins and leukocyte-endothelial interactions: growing evidence for multiple mechanisms. Lab Invest 1993;68:369.
105. Palinski W, Rosenfeld ME, Ylä-Herttuala S, et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci 1989;86:1372-1376.
106. Rosenfeld ME, Palinski W, Ylä-Herttuala S, Butler S, Witztum JL. Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis 1990;10:336-349.
107. Palinski W, Ylä-Herttuala S, Rosenfeld ME, et al. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoportein. Arteriosclerosis 1990;10:325-335.
108. Palinski W. Role of modified lipoproteins in atherosclerosis. In: Robenek H, Severs NJ, eds. Cell interactions in atherosclerosis. Ann Arbor: CRC Press, 1992;207-237.
109. Salonen JT, Ylä-Herttuala S, Yamamoto R, et al. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992;339:883-887.
110. Palinski W. Lipoprotein oxidation: mechanisms and implications for atherogenesis. In: Born GVR, Schwartz CD, eds. New horizons in coronary heart disease. London: Current Science, 1993;13.1-13.11.
111. Ylä-Herttuala S, Palinski W, Butler S, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994;14:32-40.
112. Palinski W, Ord VA, Plump AS, Breslow JL, Steinberg D, Witztum JL. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb 1994;14:605-616.
113. Ylä-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994;14:32-40.
114. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci 1995;92:821-825.
115. Tangirala RK, Casanada F, Miller E, Witztum JL, Steinberg D, Palinski W. Effect of the antioxidant N,N′-diphenyl 1,4-phenylenediamine (DPPD) on atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 1995;15:1625-1630.
116. Palinski W, Tangirala RK, Miller E, Young SG, Witztum JL. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler Thromb Vasc Biol 1995;15:1569-1576.
117. Horvai A, Palinski W, Wu H, Moulton KS, Kalla K, Glass CK. Scavenger receptor A gene regulatory elements target gene expression to macrophages and to foam cells of atherosclerotic lesions. Proc Natl Acad Sci 1995;92:5391-5395.
118. Palinski W, Witztum JL. Oxidative stress and diabetes mellitus. In: Born GVR, Schwartz CD, eds. New horizons in diabetes mellitus and coronary heart disease. London: Current Science, 1995;111-123.
119. Wissler RW, Vesselinovitch D, Davis HR, Yamada T. The composition of the evolving atherosclerotic plaque. In: Strandness DE Jr, Didisheim P, Clowes AW, Watson JT, eds. Vascular diseases: current research and clinical applications. New York: Grune & Stratton, Inc., 1987;241-256.
120. Wissler RW, Vesselinovitch D, Ko C. The effects of circulating immune complexes on atherosclerotic lesions in experimental animals and in younger and older humans. Transplant Proc 1989;21:3707-3708.
121. Wissler RW. Morphological characteristics of the developing atherosclerotic plaque. Animal studies and studies of lesions from young people. In: Weber PC, Leaf A, eds. Atherosclerosis: its pathogenesis and the role of cholesterol. New York: Raven Press, 1991;91-103.
122. Wissler RW, Quantitative microscopic morphometry of the major components of the atherosclerotic plaque. In: Wissler RW, Bond MG, Mercuri M, Tanganelli P, Weber G, Friedman G, eds. Atherosclerotic plaques: advances in imaging for sequential quantitative evaluation. New York: Plenum Press, 1991;205-212.
123. Wissler RW. Update on the pathogenesis of atherosclerosis in youth. Ann NY Acad Sci 1991;623:26-39.
124. Wissler RW. Important points in the pathogenesis of atherosclerosis. In: Gotto, AM, Jr, ed. Atherosclerosis (Scope Monograph). Kalamazoo, MI: Upjohn Co., 1992;51-88.
125. Wissler RW. Theories and new horizons in the pathogenesis of atherosclerosis and the mechanisms of clinical effects. Arch Pathol Lab Med 1992;116:1281-1291.
126. Wissler RW, PDAY collaborating investigators. New insights into the pathogenesis of atherosclerosis as revealed by PDAY. Atherosclerosis 1994;108[suppl.]: S3-S20.